Indian Pharma Industry Performance

May 2026
Presented By Sheetal Sapale

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
 Contents

o GLP 1 Agonist Market Trend

o IPM Therapy Performance

o Growth Drivers

o Top 40 Corporates

o Top 40 Brands

o Key Takeaways

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market Trend
GLP 1 Agonist Market

The Anti-obesity market is almost close to Rs. 2000 Cr today

VALUE IN RS CR CONTRIB% GROWTH

SUBGROUPS MAT VAL MAT VAL MAT VAL MAT VAL MAT VAL MAT VAL MAT MAY 5 YR
MAY 22 MAY 23 MAY 24 MAY 25 MAY 26 MAY 26 26 CAGR
GLP 1 AGONIST MKT 127 257 461 565 1906 237% 97%
TIRZEPATIDE 0 0 0 46 1207 63% 2541%
SEMAGLUTIDE 20 134 311 408 589 31% 44% 133%
DULAGLUTIDE 50 62 83 83 69 4% -17% 8%
LIRAGLUTIDE 57 61 67 28 39 2% 40% -9%

o Market is primarily driven by Tirzepatide and Semaglutide – the two blockbuster molecules in
the Anti-obesity segment
o At overall level the market seems to be a very attractive opportunity
o But one needs to dig deeper to understand if the market would continue to same trends
considering the new base
[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

The strong growth momentum shown in Apr-26 has slowed down

VALUE IN RS CR VALUE GROWTH OVER PREVIOUS MONTH
over SUBGROUPS SEP- OCT- NOV- DEC- JAN- FEB- MAR- APR- MAY- OCT- NOV- DEC- JAN- FEB- MAR- APR- MAY-
25 25 25 25 26 26 26 26 26 25 25 25 26 26 26 26 26
GLP 1 AGONIST
129 145 157 166 180 191 180 218 236 12% 8% 6% 8% 6% -6% 21% 8%
MKT
TIRZEPATIDE 80 100 108 118 131 135 114 121 136 24% 8% 10% 11% 3% -16% 6% 12%
SEMAGLUTIDE* 39 35 40 39 41 48 58 88 93 -8% 11% -2% 5% 19% 21% 50% 6%
DULAGLUTIDE 6 6 6 6 5 5 5 6 5 -6% 2% -7% -19% 2% -4% 24% -13%
LIRAGLUTIDE 4 4 3 3 3 3 3 2 2 5% -10% -5% 0% -17% -8% -12% -20%

UNITS IN 000 UNIT GROWTH OVER PREVIOUS MONTH

SUBGROUPS SEP- OCT- NOV- DEC- JAN- FEB- MAR- APR- MAY- OCT- NOV- DEC- JAN- FEB- MAR- APR- MAY-
25 25 25 25 26 26 26 26 26 25 25 25 26 26 26 26 26
GLP 1 AGONIST
268 251 248 245 238 245 276 424 464 -6% -1% -1% -3% 3% 13% 54% 9%
MKT
TIRZEPATIDE 110 106 98 101 102 101 87 93 104 -4% -8% 3% 2% -1% -14% 6% 12%
SEMAGLUTIDE* 117 104 111 108 102 114 157 295 331 -11% 7% -3% -6% 12% 38% 88% 12%
DULAGLUTIDE 16 15 15 14 12 11 11 14 12 -8% 1% -7% -18% -2% -3% 26% -15%
LIRAGLUTIDE 25 26 23 22 22 18 17 15 12 6% -10% -5% 0% -20% -8% -11% -20%

*Semaglutide is Oral + Injectables

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Generics push in market performance is slowing down

INJECTABLES - MONTHLY VAL TREND

TIRZEPATIDE - INJ SEMAGLUTIDE - INJ SEMAGLUTIDE - SOLIDS
o Tirzepatide seems to have moved
160

140 131 135 136 back to the pre-generics launch

121
120 108
118 114 levels in May 26
100
100
VAL IN RS CR

80
80
61 64 o Semaglutide injectables monthly
60
30 34 momentum seems to have slowed
40
26 27 26 24
20 9 9 12 13
18 down
24 24 27 29
22
0
SEP-25 OCT-25 NOV-25 DEC-25 JAN-26 FEB-26 MAR-26 APR-26 MAY-26

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Unit consumption seems to have created a new base

INJECTABLES - MONTHLY UNIT TREND

o Due to economical pricing, the unit
TIRZEPATIDE - INJ SEMAGLUTIDE - INJ consumption on Semaglutide has
200 190
moved up significantly, but the
180 170
160
tempo has slowed down
140
UNITS IN 000

120
100 o Tirzepatide seems to moved back to
110 106 104
80 98 101 102 101
87 93 its normal monthly trend that was
60
40
19 25
63 seen before the Semaglutide
20 6 7 11 12 generics launch
0
SEP-25 OCT-25 NOV-25 DEC-25 JAN-26 FEB-26 MAR-26 APR-26 MAY-26

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Unit consumption seems to have created a new base

INJECTABLES - MONTHLY UNIT TREND

o Due to economical pricing, the unit
TIRZEPATIDE - INJ SEMAGLUTIDE - INJ SEMAGLUTIDE - SOLIDS consumption on Semaglutide has
200 190
moved up significantly, but the
180 170
160 140
tempo has slowed down
140 126
110
UNITS IN 000

120
100
97 100 96
83 89 94 o Tirzepatide seems to moved back to
110 106 104
80 98 101 102 101 87
93 its normal monthly trend that was
60 63
40
19 25 seen before the Semaglutide
20 6 7 11 12 generics launch
0
SEP-25 OCT-25 NOV-25 DEC-25 JAN-26 FEB-26 MAR-26 APR-26 MAY-26

o Semaglutide solids have also shown

a gradual slow down in pace

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Futuristic growth of the market will depend on several parameters

INJECTABLES - MONTHLY UNIT TREND

TIRZEPATIDE - INJ SEMAGLUTIDE - INJ SEMAGLUTIDE - SOLIDS
o Patient sustainence / dropouts –
200 190 which will determine the repurchase
180 170
160 140
140 126 o How many of the eligible patients
110
have been onboarded – directly
UNITS IN 000

120 100
97 96 94
100 83 89
110
80
106
98 101 102 101
87 93
104 impacting new patient onboarding
60
63
40
19 25
20 6 7 11 12 o Government advisories – leading to
0
SEP-25 OCT-25 NOV-25 DEC-25 JAN-26 FEB-26 MAR-26 APR-26 MAY-26 stringent patient onboarding norms

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Tirzepatide moving back on a growth trajectory indicates

stickiness of superspeciality Physicians to innovator molecules

GROWTH OVER PREVIOUS MONTH

OCT- NOV- DEC- JAN- FEB- MAR- APR- MAY-
TRENDSUBGROUP 25 25 25 26 26 26 26 26
VALUE TIRZEPATIDE - INJ 24% 8% 10% 11% 3% -16% 6% 12%
GROWTH SEMAGLUTIDE - INJ 2% 35% 1% 43% 33% 42% 78% 5%
TREND SEMAGLUTIDE - SOLIDS -12% 3% -4% -13% 8% 1% 11% 7%

UNIT TIRZEPATIDE - INJ -4% -8% 3% 2% -1% -14% 6% 12%

GROWTH SEMAGLUTIDE - INJ 1% 74% 6% 54% 35% 151% 169% 12%
TREND SEMAGLUTIDE - SOLIDS -12% 3% -4% -14% 7% 6% 34% 12%

[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

Some brands under the Semaglutide umbrella continue to show

strong positive traction

MONTHLY UNITS IN 000 • Out of the 35 brands

Gr%
Incre MAY-26
(from 17 companies),
FORM BRAND COMPANY May 26 7 brands have shown upward
MAR-26 APR-26 MAY-26 over
over
Apr 26
APR 26 trend in May 26 over Apr 26
OZEMPIC
NOVO NORDISK 12 12 16 3 27%
(INNOVATOR) • Since the market growth has
SUNDAE ERIS 5 21 27 6 29%
slowed down, there are
INJECTABLES NOVELTREAT SUN 2 7 15 8 124%
brands that have shown a
SEMATRINITY SUN 2 5 7 3 66%
negative traction over Apr 26
HEPAGLIDE ALKEM 1 6 8 1 20%
SEMALIX TORRENT 4 27 33 5 19%
SOLIDS • There are chances of
SEMBOLIC TORRENT 3 19 26 6 32%
inventory build up especially
Brands with a significantly large unit base have been considered in the Semaglutide generics
that may start getting visible
[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
GLP 1 Agonist Market

To Summarize
o May 26 data suggests that Indian GLP 1 market is moving beyond the initial
launch driven phase of generic expansion.

o Semaglutide generics growth trajectory seems to be stabilizing now

o It is possible that a significant proportion of eligible patients who could not

earlier benefit from GLP 1 Agonists due to cost aspects, may now have got
onboarded.

o Demand for economical GLP 1 Agonists can be sustained only with unveiling
the unveiled eligible population pool with affordability concerns

o Positive trend in innovators despite the generic onslaught indicates sustained

physician(especially Superspecialities) confidence in evidence-based brands
[Link] Source: PHARMATRAC MAT May 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
IPM Therapy Performance
IPM Therapy Performance
The IPM has shown a Value growth of 10.9% with most of the top therapies
showing a double digit value growth
MAT May'26 MTH May'26
SUPER GROUP
SALES VAL CONT% VAL GR% UNIT GR% SALES VAL CONT% VAL GR% UNIT GR%
IPM 250757 100% 9.3% 0.9% 21805 100% 10.9% 1.4%
CARDIAC 35086 14% 14.5% 5.1% 3184 15% 13.9% 2.9%
GASTRO INTESTINAL 29202 12% 4.3% -4.5% 2680 12% 6.7% -0.1%
ANTI-INFECTIVES 28147 11% 5.7% -2.1% 2221 10% 6.1% -4.0%
ANTI DIABETIC 23693 9% 13.1% 2.6% 2151 10% 16.8% 1.3%
VIT / MIN / NUT 22266 9% 7.9% 1.1% 2024 9% 12.5% 5.9%
RESPIRATORY 19660 8% 12.2% 8.9% 1411 6% 12.3% 10.0%
PAIN / ANALGESICS 17329 7% 6.7% -2.0% 1496 7% 8.4% -1.7%
NEURO / CNS 16937 7% 10.7% 1.4% 1488 7% 11.0% 1.1%
DERMA 16191 6% 8.1% -0.8% 1404 6% 11.3% 1.5%
GYNAECOLOGICAL 7968 3% 9.0% 2.3% 702 3% 9.5% 1.4%
BLOOD RELATED 7385 3% 8.0% -0.2% 674 3% 11.0% -0.2%
ANTI-NEOPLASTICS 5971 2% 11.8% 12.0% 539 2% 13.4% 7.6%
OPHTHAL / OTOLOGICALS 4691 2% 6.3% -0.3% 407 2% 5.2% -5.7%
UROLOGY 4527 2% 15.5% 6.8% 407 2% 15.1% 6.8%
HORMONES 3618 1% 4.8% -2.8% 302 1% 3.4% -6.9%
VACCINES 2510 1% 21.9% 15.7% 223 1% 17.6% 15.5%
OTHERS 1883 1% 10.2% 9.3% 171 1% 16.1% 12.5%
STOMATOLOGICALS 1722 1% 8.9% -0.7% 152 1% 9.4% -1.1%
SEX STIMULANTS / REJUV 1319 1% 6.4% -1.0% 121 1% 14.2% 7.0%
ANTI MALARIALS 652 0% 0.2% 2.4% 47 0% -4.5% -3.7%

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Growth Drivers
IPM Monthly Growth Drivers

All the three growth levers are positive for the month of May 26

8.8 6.1 6.3 5.3 6.1 9.9 7.7 8.7 7.5 7.5 7.8 7.2 8.0 7.9 8.7 7.3 9.5 9.1 10.6 10.2 11.0 10.1 10.3 10.9

Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May- Jun- Jul- Aug- Sep- Oct- Nov- Dec- Jan- Feb- Mar- Apr- May-
24 24 24 24 24 24 24 25 25 25 25 25 25 25 25 25 25 25 25 26 26 26 26 26
NP GR 2.6 2.7 2.7 2.4 2.7 2.7 2.6 2.6 2.4 2.2 2.3 2.2 2.4 2.5 2.4 2.5 2.6 2.9 3.3 3.4 3.5 3.5 3.6 3.8
Price GR 6.0 5.5 5.2 5.3 5.2 5.4 5.3 5.3 5.2 5.2 5.1 5.0 5.3 5.6 5.6 5.5 5.6 5.5 5.5 5.4 5.3 5.5 5.6 5.7
Vol GR 0.2 -2.1 -1.7 -2.4 -1.8 1.8 -0.2 0.9 -0.2 0.1 0.4 0.1 0.2 -0.2 0.6 -0.6 1.2 0.6 1.8 1.4 2.2 1.1 1.0 1.3

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Therapy Growth Drivers

Except a few, all the top therapies have shown a positive Volume growth for the month of
May 26
MAY 26 MTH GROWTH DRIVERS
10.9 13.9 6.1 6.7 16.8 12.5 12.3 8.4 11.3 11.0 9.5 11.0 13.4 5.2 3.4 15.1

VIT/MIN/ PAIN/ NEURO / BLOOD ANTI- OPTH/ HORMONE

IPM CARDIAC ANTI-INF GASTRO ANTI-DIAB RESPI DERMA GYNAEC UROLOGY
NUTR ANAL CNS REL NEOP OTOL S
NP GR 3.8 1.0 1.8 2.6 12.9 5.2 4.0 2.5 3.4 2.1 6.4 1.8 6.9 1.9 0.4 2.1
Price GR 5.7 6.9 4.1 6.2 5.4 6.2 6.9 6.1 6.1 6.1 5.0 6.0 1.6 4.7 3.1 6.6
Vol GR 1.3 6.0 0.2 -2.1 -1.5 1.1 1.5 -0.2 1.8 2.8 -1.9 3.3 4.8 -1.4 0.0 6.3

MAY 26 MAT GROWTH DRIVERS

9.3 14.5 5.7 4.3 13.1 7.9 12.2 6.7 8.1 10.7 9.0 8.0 11.8 6.3 4.8 15.5

VIT/MIN/ PAIN/ NEURO / BLOOD ANTI- OPTH/ HORMON

IPM CARDIAC ANTI-INF GASTRO ANTI-DIAB RESPI DERMA GYNAEC UROLOGY
NUTR ANAL CNS REL NEOP OTOL ES
NP GR 2.8 0.8 1.3 2.1 9.6 3.4 3.0 1.8 2.6 1.6 4.7 1.6 3.3 1.7 0.3 1.6
Price GR 5.6 6.8 4.0 6.5 3.6 6.0 7.4 5.7 5.8 6.0 5.0 5.6 1.5 4.7 3.2 7.5
Vol GR 1.0 7.0 0.3 -4.3 -0.2 -1.5 1.8 -0.8 -0.3 3.0 -0.6 0.7 7.0 0.0 1.3 6.5

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Top 40 Corporates
Top Corporates Rank 1 - 20

For the month of May 26 majority of the top players have shown an encouraging Value growth.
MAT May'26 MTH May'26
CORPORATE
SALES VAL RANK CONT% VAL GR% UNIT GR% SALES VAL RANK CONT% VAL GR% UNIT GR%

IPM 250757 100% 9.3% 0.9% 21805 100% 10.9% 1.4%

SUN* 21168 1 8.4% 12.9% 3.8% 1806 1 8.3% 11.5% 3.3%
ABBOTT* 14717 2 5.9% 6.2% 2.7% 1292 2 5.9% 10.8% 10.9%
CIPLA 14698 3 5.9% 10.4% 8.5% 1216 3 5.6% 12.4% 10.2%
MANKIND* 13777 4 5.5% 6.8% 1.2% 1207 4 5.5% 11.7% 3.8%
TORRENT 12644 5 5.0% 14.1% -0.1% 1181 5 5.4% 17.8% -0.2%
ALKEM* 10271 6 4.1% 9.9% 0.4% 874 7 4.0% 10.2% -0.2%
INTAS 10056 7 4.0% 13.9% 4.4% 911 6 4.2% 19.8% 6.4%
LUPIN 8833 8 3.5% 11.1% 1.3% 813 8 3.7% 13.5% 2.6%
ZYDUS* 8026 9 3.2% 12.1% -4.5% 723 9 3.3% 14.0% -12.0%
DR. REDDYS 7901 10 3.2% 11.4% -1.1% 660 10 3.0% 8.0% -7.8%
MACLEODS 7490 11 3.0% 9.3% 4.0% 639 11 2.9% 8.7% 1.6%
ARISTO PHARMA 7021 12 2.8% 7.8% 0.1% 600 12 2.8% 12.0% 2.8%
EMCURE* 6022 13 2.4% 0.9% -3.1% 515 13 2.4% -1.3% -14.6%
GSK 5237 14 2.1% 7.9% -4.8% 419 17 1.9% 9.5% -4.0%
GLENMARK 5234 15 2.1% 13.4% 3.8% 482 14 2.2% 16.6% 6.2%
USV 5121 16 2.0% 12.7% 4.5% 463 15 2.1% 14.1% 6.0%
IPCA 4873 17 1.9% 11.0% 4.8% 427 16 2.0% 14.0% 5.5%
MICRO 4005 18 1.6% 4.5% -0.8% 324 18 1.5% 5.9% 2.1%
ERIS LS* 3136 19 1.3% 9.9% -1.8% 286 19 1.3% 9.2% -10.9%
ALEMBIC 2786 20 1.1% -2.8% -9.8% 221 21 1.0% -3.2% -11.7%

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Top Corporates Rank 21 – 40

For the month of May 26 majority of the top players have shown an encouraging Value growth.

MAT May'26 MTH May'26

CORPORATE
SALES VAL RANK CONT% VAL GR% UNIT GR% SALES VAL RANK CONT% VAL GR% UNIT GR%

IPM 250757 100% 9.3% 0.9% 21805 100% 10.9% 1.4%

PFIZER* 2659 21 1.1% 5.5% -8.0% 231 20 1.1% 9.1% -7.9%
FDC 2105 22 0.8% 3.1% -1.7% 208 22 1.0% 0.6% 13.3%
LA RENON 2081 23 0.8% 17.0% 5.8% 192 23 0.9% 21.2% 7.2%
AJANTA 2008 24 0.8% 14.8% 8.3% 186 24 0.9% 22.2% 16.2%
SANOFI INDIA 1981 25 0.8% 7.1% 13.9% 159 26 0.7% 8.1% 9.4%
CORONA 1721 26 0.7% 17.7% 6.0% 163 25 0.7% 21.5% 3.2%
HIMALAYA 1696 27 0.7% 0.6% -13.6% 145 27 0.7% -1.5% -11.1%
PROCTER AND GAMBLE 1615 28 0.6% 9.3% 1.2% 139 28 0.6% 15.1% 6.3%
INDOCO 1420 29 0.6% 7.5% -1.0% 110 35 0.5% 4.1% -2.3%
BAYER 1359 30 0.5% 10.8% -12.8% 111 33 0.5% 11.8% -4.5%
FRANCO 1358 31 0.5% 5.1% -1.5% 112 32 0.5% 1.7% -11.9%
SYSTOPIC 1272 32 0.5% 8.5% 4.6% 110 34 0.5% 10.0% 4.6%
CADILA 1267 33 0.5% -4.0% -12.1% 114 31 0.5% 7.6% 6.9%
NUTRICIA 1256 34 0.5% 15.3% 3.6% 125 29 0.6% 16.4% 1.6%
ELI LILLY 1236 35 0.5% 257.0% -8.0% 114 30 0.5% 198.2% -33.1%
HETERO 1226 36 0.5% 6.8% -3.0% 104 37 0.5% 5.8% -0.2%
BLUE CROSS 1211 37 0.5% 4.3% -0.8% 100 39 0.5% 2.9% -1.7%
FOURRTS 1153 38 0.5% 9.6% 2.8% 102 38 0.5% 10.7% -2.0%
HEGDE & HEGDE 1092 39 0.4% -0.4% -4.9% 94 41 0.4% 8.2% -0.9%
ASTRAZENECA 1088 40 0.4% 17.7% 15.6% 106 36 0.5% 22.3% 11.2%

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Top 40 Brands
Top Brands Rank 1-20

Mounjaro maintained it’s 1st position at MAT and Month level.

Augmentin & Glycomet GP at 2nd and 3rd position for MAT Period.
Zerodol SP, Betadine, Cilacar, Telma & Budecort show a robust double-digit Val and Unit Gr%.
MAT May'26 MTH May'26
CORPORATE BRANDS
SALES VAL RANK VAL GR% UNIT GR% SALES VAL RANK VAL GR% UNIT GR%
ELI LILLY MOUNJARO 1095 1 2297% 685.5% 109 1 378.9% 10.8%
GSK AUGMENTIN 930 2 13.5% 9.5% 59 11 13.2% 7.4%
USV GLYCOMET GP 918 3 13.4% 1.7% 84 2 14.4% 3.0%
CIPLA FORACORT 854 4 7.4% -0.3% 72 4 14.7% -3.0%
ALKEM* PAN 849 5 8.9% 1.6% 77 3 9.9% 5.1%
ABBOTT* (NOVO) MIXTARD 802 6 4.7% 14.9% 62 9 -5.8% 8.1%
IPCA ZERODOL SP 754 7 17.4% 10.0% 68 5 27.9% 19.3%
ALKEM* CLAVAM 721 8 8.6% 3.0% 55 14 6.7% 1.7%
HIMALAYA LIV.52 708 9 -5.5% -21.1% 65 7 -5.6% -14.1%
ALKEM* PAN D 698 10 4.5% -5.7% 61 10 0.7% -8.5%
ARISTO PHARMA MONOCEF 679 11 4.3% 2.6% 53 16 2.5% -0.1%
ABBOTT* UDILIV 657 12 3.1% -6.2% 56 13 2.3% -8.5%
ABBOTT* THYRONORM 626 13 12.8% 10.5% 57 12 8.5% 7.6%
CIPLA DUOLIN 618 14 14.0% 10.3% 43 24 10.7% 9.9%
WIN-MEDICARE BETADINE 583 15 5.0% 0.0% 51 18 14.1% 13.3%
TORRENT CILACAR 577 16 23.9% 12.6% 62 8 33.2% 20.0%
GLENMARK TELMA 573 17 13.9% 14.5% 54 15 14.2% 12.4%
ABBOTT* (NOVO) RYZODEG 567 18 -5.0% -4.5% 49 20 8.4% 8.2%
USV ECOSPRIN AV 554 19 21.3% 1.2% 53 17 31.8% 7.4%
CIPLA BUDECORT 554 20 16.8% 14.7% 40 30 30.4% 24.0%

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
Top Brands Rank 21 – 40

Manforce, Levipil, Lantus, Electral, Rosuvas, Dytor, Chymoral Forte, Levera, T Bact, Gabapin NT and
Aciloc show a robust double-digit Val and Unit Gr%
MAT May'26 MTH May'26
CORPORATE BRANDS
SALES VAL RANK VAL GR% UNIT GR% SALES VAL RANK VAL GR% UNIT GR%
MANKIND* MANFORCE 534 21 3.5% 2.7% 51 19 20.2% 19.5%
SUN* LEVIPIL 507 22 15.0% 12.1% 45 21 16.2% 13.1%
SANOFI INDIA LANTUS 497 23 16.7% 16.1% 41 27 12.4% 11.0%
JANSSEN ULTRACET 489 24 2.0% -4.3% 43 25 -4.5% -4.2%
FRANCO DEXORANGE 487 25 3.8% -6.3% 44 23 2.7% -6.6%
FDC ELECTRAL 472 26 -3.6% 2.0% 67 6 12.0% 30.0%
SUN* ROSUVAS 458 27 5.6% -0.9% 44 22 23.9% 14.3%
ASTRAZENECA BRILINTA 450 28 30.2% 22.1% 43 26 13.7% 7.9%
CIPLA DYTOR 433 29 23.1% 13.8% 40 29 17.4% 16.3%
ARISTO PHARMA PANTOP 425 30 1.8% -2.2% 38 33 -1.5% -10.3%
ABBOTT* VERTIN 422 31 20.3% 6.8% 40 28 15.0% 4.9%
APEX ZINCOVIT 413 32 4.6% -3.6% 35 45 8.1% -3.4%
GSK CALPOL 406 33 -2.9% -3.6% 32 50 0.6% 0.3%
TORRENT CHYMORAL FORTE 391 34 15.3% 8.0% 38 32 30.4% 19.1%
SUN* GEMER 391 35 13.5% 3.9% 35 44 16.8% 5.2%
INTAS LEVERA 390 36 12.4% 8.7% 37 36 22.6% 19.5%
GSK T BACT 389 37 11.0% 7.5% 30 61 17.0% 12.4%
INTAS GABAPIN NT 382 38 16.7% 12.1% 36 38 25.9% 17.8%
MICRO DOLO 379 39 -3.0% -5.0% 30 60 6.6% 2.5%
CADILA ACILOC 378 40 -0.6% -13.0% 39 31 18.7% 14.4%

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
 To Summarize

• The IPM has shown a Value growth of 10.9% with all the therapies showing a positive Value
growth.

• All the three growth levers are positive for the month of May - 26

• For the month of May 26 majority of the Top players have shown an encouraging Value growth

• At MAT May 26 time period, Mounjaro maintained it’s 1st position; Augmentin and Glycomet GP
at 2nd and 3rd position.

[Link] Source: PHARMATRAC MAT MAY 2026 VAL IN CR ; UNITS IN 000 | The Content of this Industry Presentation is property of Pharmarack. Any replication/publication without authorization would amount to legal action
 Thank you

Sheetal Sapale
sheetals@[Link]
+919819366690
sit us at: [Link]

Visit us at: [Link]